3. Learning Objectives

4. Metabolic Abnormalities Associated With T2D

5. CV Events With PPAR-gamma Agonists

6. Effect of Fibrates on CV Outcomes A Systematic Review and Meta-analysis

7. ACCORD Lipid Hazard Ratios for the Primary Outcome

9. Pioglitazone Meta-analysis Heart Failure & MI

10. Dual PPAR a/g Agonists

11. AleCardio Aleglitazar (PPAR a/g Agonist) in Patients With T2D and ACS

12. AleCardio Efficacy and Safety Outcomes

13. AleCardio Glycemic Control and Lipoprotein Effects

14. Genes Regulated by Glitazones

15. Older Antidiabetic Drugs and CV Benefit/Harm

16. SAVOR-TIMI 53 Clinical End Points: Saxagliptin (DPP4 Inhibitor) vs Placebo

17. SAVOR-TIMI 53 Hospitalization for Heart Failure Stratified by NT-proBNP Quartiles

18. SAVOR-TIMI 53 Safety Endpoints

19. EXAMINE Safety End Points: Alogliptin (DPP4 Inhibitor) vs Placebo

20. EXAMINE Heart Failure Outcomes

21. Mechanism of Heart Failure

22. Ongoing CVD Outcomes Trials in Type 2 Diabetes

23. Clinical Trial Design Considerations

24. AlePrevent Aleglitazar in Patients With Stable CVD and Glucose Abnormalities

25. Newer Antidiabetic Drugs & CV Risk Reduction

26. Concluding Remarks

27. Abbreviations

28. Abbreviations (cont)

29. Abbreviations (cont)

30. References

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)

36. References (cont)

37. References (cont)